title: Two vs Three Doses of Human Papillomavirus Vaccine: New Policy for the Second Decade of the Vaccination Program.
authors.affiliation: Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, US Centers for Disease Control and Prevention, Atlanta, Georgia.
authors.forename: Lauri E
authors.initials: LE
authors.lastname: Markowitz
authors.affiliation: Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, US Centers for Disease Control and Prevention, Atlanta, Georgia.
authors.forename: Elissa
authors.initials: E
authors.lastname: Meites
authors.affiliation: Division of High-Consequence Pathogens and Pathology, National Center for Emerging and Zoonotic Infectious Diseases, US Centers for Disease Control and Prevention, Atlanta, Georgia.
authors.forename: Elizabeth R
authors.initials: ER
authors.lastname: Unger
mesh_terms: D000293:Adolescent; D000328:Adult; D026683:Advisory Committees; D000367:Age Factors; D000914:Antibodies, Viral / Q000097:blood; D002487:Centers for Disease Control and Prevention, U.S.; D002648:Child; D017277:Drug Approval; D005260:Female; D000068857:Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 / Q000276:immunology; D006801:Humans; D017589:Immunization Programs; D007115:Immunization Schedule; D008297:Male; D053918:Papillomavirus Vaccines / Q000008:administration & dosage* / Q000276:immunology; D014481:United States; D014486:United States Food and Drug Administration; D055815:Young Adult
chemical_list: D000914:Antibodies, Viral; D000068857:Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18; D053918:Papillomavirus Vaccines